secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2021-11-18T23:59:59+00:00
Accession:  0001193125-21-333831
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics appoints Bridget Martell, M.D. to Board of Directors
------------------------------------------------------------------------

- Dr. Martell appointed as Class III director; term expires at 2023 annual meeting.
- She receives $35,000 annual retainer (prorated) and initial option grant of 30,000 shares.
- Board size increased from seven to eight directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312521333831/0001193125-21-333831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312521333831/d437129d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-333831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer